FDA Brief

Warning letters Drugs

FDA warning letter to

OraLabs, Inc.

High riskIssued Mar 11Posted Mar 17Center for Drug Evaluation and Research (CDER)

FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.

What happened

FDA inspected OraLabs' drug manufacturing facility in Parker, Colorado, from September 22 to 26, 2025. Investigators found the company released multiple batches of over-the-counter drug products without microbiological release testing, and that its quality unit approved and shipped those lots. FDA also found the company's investigations into microbial test failures were incomplete, including one where high total aerobic counts identified as Bacillus cereus were set aside as invalid without sound scientific reason.

What FDA found

  1. The company released batches of OTC drugs without testing them for objectionable microorganisms, and did so only when a customer asked.

    21 CFR 211.165(b)
  2. The company wrote a memo concluding no microbial testing was needed, even though its own records showed microbial growth in its products.

    21 CFR 211.165(b)
  3. The company threw out a high total aerobic count result that identified Bacillus cereus, without adequate scientific justification.

    21 CFR 211.192
  4. Investigations into microbial test failures often ended with no clear root cause, no environmental sampling, and weak corrective actions, yet the lots were still released.

    21 CFR 211.192

What FDA wants

Within 15 working days, respond in writing with what has been corrected and how recurrence will be prevented. FDA also asks for independent assessments of the lab and manufacturing operations, a risk assessment of already-distributed product, completed investigations of contaminated batches, and testing of retained samples of all unexpired U.S. batches.

Who should pay attention

  • brands that use OraLabs as a contract manufacturer of OTC drugs
  • retailers and distributors selling store-brand OTC products made at this site
  • quality teams at other OTC makers that rely on customer-request-only microbial testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk